drugset / Trial / NCT07649928
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
ESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).
Timeline
- Start
- 2026-05-18
- Primary completion
- 2028-12
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES502 | Protein / enzyme biologic | 20 ug | — |
| Subject | ES502 | Protein / enzyme biologic | 60 ug | — |
| Subject | ES502 | Protein / enzyme biologic | 180 ug | — |
| Subject | ES502 | Protein / enzyme biologic | 540 ug | — |